The pharma sector received an unexpected boost during the pandemic: an enhanced public image. But maintaining this perception is not an easy task. Now they must demonstrate that their priorities are people, not profits, and deliver long-term value to be appreciated by their stakeholders.
To achieve this, focusing on diversity, equity and inclusion (DEI) is critical, say GEP experts.
Our new white paper, 3 Focus Areas for Pharma Companies to Achieve Greater Diversity, Equity and Inclusion, explains how empowering procurement to drive DEI across three key stakeholder groups — suppliers, workforce and patients — can help pharma companies close the health gap between demographics and allow societies to thrive.
This paper is essential reading for pharma procurement and business leaders who want to ensure a clear path toward achieving DEI goals.